全文获取类型
收费全文 | 111227篇 |
免费 | 8592篇 |
国内免费 | 5077篇 |
专业分类
耳鼻咽喉 | 255篇 |
儿科学 | 3288篇 |
妇产科学 | 690篇 |
基础医学 | 7691篇 |
口腔科学 | 292篇 |
临床医学 | 9349篇 |
内科学 | 63150篇 |
皮肤病学 | 434篇 |
神经病学 | 2109篇 |
特种医学 | 2310篇 |
外国民族医学 | 15篇 |
外科学 | 8986篇 |
综合类 | 7031篇 |
现状与发展 | 16篇 |
一般理论 | 4篇 |
预防医学 | 3853篇 |
眼科学 | 140篇 |
药学 | 6924篇 |
72篇 | |
中国医学 | 512篇 |
肿瘤学 | 7775篇 |
出版年
2024年 | 155篇 |
2023年 | 3197篇 |
2022年 | 5131篇 |
2021年 | 5812篇 |
2020年 | 5114篇 |
2019年 | 3712篇 |
2018年 | 4570篇 |
2017年 | 4016篇 |
2016年 | 3960篇 |
2015年 | 4301篇 |
2014年 | 8037篇 |
2013年 | 7352篇 |
2012年 | 7071篇 |
2011年 | 7096篇 |
2010年 | 6035篇 |
2009年 | 5338篇 |
2008年 | 4793篇 |
2007年 | 4991篇 |
2006年 | 4491篇 |
2005年 | 3900篇 |
2004年 | 3105篇 |
2003年 | 3001篇 |
2002年 | 2647篇 |
2001年 | 2376篇 |
2000年 | 1913篇 |
1999年 | 1709篇 |
1998年 | 1083篇 |
1997年 | 710篇 |
1996年 | 801篇 |
1995年 | 838篇 |
1994年 | 648篇 |
1993年 | 596篇 |
1992年 | 687篇 |
1991年 | 643篇 |
1990年 | 664篇 |
1989年 | 600篇 |
1988年 | 560篇 |
1987年 | 419篇 |
1986年 | 313篇 |
1985年 | 257篇 |
1984年 | 253篇 |
1983年 | 189篇 |
1982年 | 221篇 |
1981年 | 181篇 |
1980年 | 153篇 |
1979年 | 145篇 |
1978年 | 161篇 |
1977年 | 152篇 |
1976年 | 113篇 |
1975年 | 103篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
《Surgery for obesity and related diseases》2019,15(4):643-649
BackgroundMechanisms of metabolic improvement after bariatric surgery remain incompletely understood. Intestinal glucose uptake is increased after gastric bypass in rodents, potentially contributing to reduced blood glucose and type 2 diabetes remission.ObjectiveWe assessed whether intestinal glucose uptake is increased in humans after gastric surgery.SettingUniversity Hospital, United States.MethodsIn a retrospective, case-control cohort study, positron emission tomography-computerized tomography scans performed for clinical indications were analyzed to quantify intestinal glucose uptake in patients with or without history of gastric surgery. We identified 19 cases, defined as patients over age 18 with prior gastric surgery (Roux-en-Y gastric bypass [n = 10], sleeve gastrectomy [n = 1], or Billroth I [n = 2] or II gastrectomy [n = 6]), and 43 controls without gastric surgery, matched for age, sex, and indication for positron emission tomography-computerized tomography. Individuals with gastrointestinal malignancy or metformin treatment were excluded. Images were obtained 60 minutes after 18F-fluorodeoxyglucose injection (4.2 MBq/kg), and corrected by attenuation; noncontrast low-dose computerized tomography was obtained in parallel. Fused and nonfused images were analyzed; standardized uptake values were calculated for each region by volumes of interest at the region of highest activity.ResultsBoth standardized uptake values maximum and mean were significantly increased by 41% to 98% in jejunum, ascending, and transverse colon in patients with prior gastric surgery (P < .05 versus controls).ConclusionIntestinal glucose uptake is increased in patients with prior gastric surgery. Prospective studies are important to dissect the contributions of weight loss, dietary factors, and systemic metabolism, and to determine the relationship with increased insulin-independent glucose uptake and reductions in glycemia. 相似文献
62.
63.
64.
65.
66.
67.
68.
《Diagnostic microbiology and infectious disease》2020,96(1):114920
We evaluated the performance of the Luminex ARIES® C. difficile Assay on 984 stool specimens prospectively collected from patients being tested for CDI at 4 clinical laboratories in the United States. Results were compared to direct and enriched toxigenic culture. Positive percent agreement (PPA) of the ARIES® C. difficile Assay was 98.1% versus direct toxigenic culture, and sensitivity versus direct plus enriched toxigenic culture was 90.5%. Negative percent agreement (NPA) of the ARIES® C. difficile Assay against direct culture was 92.6%, and specificity versus direct plus enriched toxigenic culture was 95.8%. The ARIES® C. difficile Assay was also compared to the results of routine (molecular, antigen, and/or toxin) methods for C. difficile testing used at each institution. The PPA of the ARIES® C. difficile Assay ranged from 82.9% to 100%. NPA values against these commercial assays ranged from 94.5% to 100%. 相似文献
69.
《Genetics in medicine》2020,22(3):590-597
PurposeAcute intermittent porphyria (AIP) is a rare inborn error of heme biosynthesis characterized by life-threatening acute attacks. Few studies have assessed quality of life (QoL) in AIP and those that have had small sample sizes and used tools that may not have captured important domains.MethodsBaseline data from the Porphyrias Consortium’s Longitudinal Study were obtained for 259 patients, including detailed disease and medical history data, and the following Patient-Reported Outcomes Measurement Information System (PROMIS) scales: anxiety, depression, pain interference, fatigue, sleep disturbance, physical function, and satisfaction with social roles. Relationships between PROMIS scores and clinical and biochemical AIP features were explored.ResultsPROMIS scores were significantly worse than the general population across all domains, except depression. Each domain discriminated well between asymptomatic and symptomatic patients with symptomatic patients having worse scores. Many important clinical variables like symptom frequency were significantly associated with domain scores in univariate analyses, showing responsiveness of the scales, specifically pain interference and fatigue. However, most regression models only explained ~20% of the variability observed in domain scores.ConclusionPain interference and fatigue were the most responsive scales in measuring QoL in this AIP cohort. Future studies should assess whether these scales capture longitudinal disease progression and treatment response. 相似文献
70.
《Journal of vascular and interventional radiology : JVIR》2020,31(1):25-34
PurposeTo investigate the safety of yttrium-90 radioembolization in combination with checkpoint inhibitor immunotherapy for the treatment of hepatocellular carcinoma (HCC).Materials and MethodsThis single-center retrospective study included 26 consecutive patients with HCC who received checkpoint inhibitor immunotherapy within 90 days of radioembolization from April 2015 to May 2018. Patients had preserved liver function (Child-Pugh scores A–B7) and either advanced HCC due to macrovascular invasion or limited extrahepatic disease (21 patients) or aggressive intermediate stage HCC that resulted in earlier incorporation of systemic immunotherapy (5 patients). Clinical documentation, laboratory results, and imaging results at 1- and 3-month follow-up intervals were reviewed to assess treatment-related adverse events and treatment responses.ResultsThe median follow-up period after radioembolization was 7.8 months (95% confidence interval [CI], 5.6–11.8). There were no early (30-day) mortality or grades 3/4 hepatobiliary or immunotherapy-related toxicities. Delayed grades 3/4 hepatobiliary toxicities (1–3 months) occurred in 2 patients in the setting of HCC disease progression. One patient developed pneumonitis. The median overall survival from first immunotherapy was 17.2 months (95% CI, 10.9–23.4). The median overall survival from first radioembolization was 16.5 months (95% CI, 6.6–26.4). From first radioembolization, time to tumor progression was 5.7 months (95% CI, 4.2–7.2), and progression-free survival was 5.7 months (95% CI, 4.3–7.1).ConclusionsRadioembolization combined with checkpoint inhibitor immunotherapy in cases of HCC appears to be safe and causes limited treatment-related toxicity. Future prospective studies are needed to identify the optimal combination treatment protocols and evaluate the efficacy of combination therapy. 相似文献